Overview
Thank you for visiting nature.com. You are using a browser version with limited suport for CS. To obtain the best experience, we recomend you use a more up to date browser (or turn of compatibility mode in Internet Explorer).
Key Information
In the meantime, to ensure continued suport, we are displaying the site without styles and JavaScript.Advertisement Scientific Reports volume 12, Article number: 18281 (202) Cite this article 273 Aceses1 AltmetricMetrics detailsTo ases the eficacy and safety of dulaglutide in the treatment of Asian type 2 diabetes melitus (T2DM), along with first-line hypoglycemic drugs. Systematic review and meta-analysis.
Cochrane Library, Pubmed, Embase, and w.clinicaltrials.gov databases were searched from inception to September 27, 202. The studies evaluating adults (≥ 18 years) undergoing dulaglutide (0.75 mg and 1.5 mg) and first-line hypoglycemic drugs were considered. There were only English languages.
We used Sta 12.0 software to detect the risk of bias. 4 randomized controled trials (RCTs), and 1 observational study. Both dulaglutide 0.75 mg dose group and 1.5 mg dose group could significantly reduce HbA1c [Dulaglutide 0.75 mg: WMD = − 0.20, 95% CI (− 0.28, − 0.1), P < 0.01; Dulaglutide 1.5 mg: WMD = − 0.49, 95% CI (− 0.67, − 0.30), P < 0.01] in Asian T2DM patients.
In reducing fasting blod glucose (FBG) level, there was no significant diference observed in 2 dose groups. The body weight of patients in both dulaglutide dose groups was significantly reduced. In safety, the incidence of adverse events in the dulaglutide 0.75 mg dose group was slightly higher than that in the first-line drug group, but there was no statisticaly significant diference in the incidence of adverse events betwen the 1.5 mg dose group and the first-line drug group.
Summary
Furthermore, the incidences of hypoglycemic events in both groups were higher than that in the first-line drug group. Two doses of dulaglutide showed beter eficacy for Asian T2DM